Applications

Chimeric antigen receptor (CAR) technology has transformed immunotherapy, providing a potent mechanism for reprogramming the immune system to target specific cells. Protheragen offers the EndureCART^TM technology platform, enabling the creation and assembly of CAR molecules aimed at particular targets to enhance CAR-T cell therapy efficacy. We provide comprehensive CAR-T therapy development services across various cell immunotherapy and disease domains.

Therapeutic Applications

The success in treating B-cell malignancies has showcased the therapeutic promise of CAR-T cells against cancer. Efforts are ongoing to broaden the application of engineered T cells to various conditions, including infections and autoimmune diseases. Employ our technology platform to refine CAR-T design and elevate its therapeutic effectiveness across a spectrum of disease domains.

Multiple Disease Domains

Hematological Malignancies

CAR T cell therapy has emerged as a groundbreaking therapeutic for specific cancers, particularly hematological malignancies like leukemia and lymphoma.

Solid Tumors

Advancements are being made to optimize CAR design to tackle the intricate solid tumor microenvironment, enhance tumor recognition, and bolster efficacy.

Autoimmune Diseases

CAR cell therapy shows potential in treating autoimmune disorders by targeting autoreactive immune cells that attack healthy tissues and selectively eliminating pathogenic self-reactive cells.

Neurological Diseases

Customized CAR designs can target specific antigens present in neurological disorders, offering a fresh approach to mobilizing the immune system against these neurological diseases.

Infectious

By reprogramming T cells to target infected cells expressing distinct antigens, CAR technology presents a hopeful avenue for boosting the immune response against pathogens.

Furthermore, CAR-T therapy holds promise for application in fibrotic diseases such as heart, liver, lung, and kidney fibrosis, as well as age-related conditions. However, research outside of oncology remains in its early stages. The table below outlines the progress of CAR-T development across various diseases.

Table 1 Therapeutic Applications of CAR-T

Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Development of Multiple CAR-T Therapies

Our EndureCART^TM technology platform supports developing autologous and allogeneic CAR-T therapies. This dual capability not only expands therapy options but also expedites the development process, making advanced cellular therapies more accessible and efficacious in combating cancer and other illnesses.

• Autologous CAR-T Cell Therapy: This approach involves harvesting an individual's T cells, and genetically modifying them to express CARs that target cancer cells specifically. Utilizing the individual's immune system reduces the risk of rejection and enhances therapy efficacy.
• Allogeneic CAR-T Cell Therapy: This method utilizes T cells from healthy donors, engineered to express CARs for cancer cell recognition and destruction. Additionally, these cells undergo genetic editing to minimize autoimmune responses in individuals. Allogeneic T cells offer various benefits, including the capacity for large-scale CAR T cell production, ensuring immediate availability for multiple individuals.

Our One-stop Solution

With our expertise and cutting-edge EndureCART^TM technology platform, we specialize in providing end-to-end solutions for clients, ensuring a seamless and effective development process for their CAR-T therapies. Our services cover every stage of development, aimed at hastening the progress of CAR-T therapies tailored to each client's unique requirements.

Our dedication to excellence, innovation, and personalized service guarantees that clients receive top-tier support throughout the development of their CAR-T therapies. For further information and pricing details on our platforms, please feel free to contact us.

For research use only, not for clinical use.